Latest news
Insilico Medicine nominates AI-designed candidate for ocular diseases - Drug Target ReviewDrug Target Review · Mon, 10 Aug 2026 13:19:11 GMTHow Insilico Medicine Is Using AI To Reinvent Drug Discovery - ForbesForbes · Fri, 07 Aug 2026 06:07:08 GMTInsilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, as Preclinical Candidate (PCC) for Ocular Diseases, Inflammatory Disorders and Aging - insilico.cominsilico.com · Thu, 06 Aug 2026 09:47:23 GMTInsilico Medicine highlights AI-powered biological target discovery for rare sinonasal cancer - News-MedicalNews-Medical · Tue, 04 Aug 2026 16:02:00 GMTInsilico Medicine launches AI drug discovery benchmarking platform - Drug Target ReviewDrug Target Review · Fri, 31 Jul 2026 07:00:00 GMTInsilico Medicine Launches the Industry's First Drug Discovery and Development (DDD) Benchmark as a Service, to Evaluate Frontier AI and Foundation Models on Real-World Science - insilico.cominsilico.com · Thu, 30 Jul 2026 07:00:00 GMTInsilico Medicine Receives FDA Fast Track Designation for ISM6331, the AI-driven Pan-TEAD Inhibitor, in Advanced Mesothelioma - insilico.cominsilico.com · Tue, 28 Jul 2026 07:00:00 GMT